Your browser doesn't support javascript.
loading
Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison.
Mahon, Ronan; Tiwari, Santosh; Koch, Mirja; Ferraris, Matias; Betts, Keith A; Wang, Yan; Gao, Sophie; Proot, Pascal.
Afiliação
  • Mahon R; Novartis Ireland Limited, Dublin, D04A9N6, Ireland.
  • Tiwari S; Novartis Healthcare Pvt. Ltd, Hyderabad, 500081, India.
  • Koch M; Novartis Pharma AG, Basel, CH-4056, Switzerland.
  • Ferraris M; Novartis Pharma AG, Basel, CH-4056, Switzerland.
  • Betts KA; Analysis Group Inc, Los Angeles, CA 90071, USA.
  • Wang Y; Analysis Group Inc, Los Angeles, CA 90071, USA.
  • Gao S; Analysis Group Inc, Los Angeles, CA 90071, USA.
  • Proot P; Ghent University Hospital, Ghent, 9000, Belgium.
J Comp Eff Res ; 13(3): e230122, 2024 03.
Article em En | MEDLINE | ID: mdl-38174577
ABSTRACT

Aim:

To compare the efficacy of erenumab versus rimegepant as preventive treatment for patients with episodic and chronic migraine using an anchor-based matching-adjusted indirect comparison.

Methods:

Patients from two phase II/III trials for erenumab (NCT02066415 and NCT02456740) were pooled and weighted to match on the baseline effect modifiers (age, sex, race, baseline monthly migraine days [MMDs], and history of chronic migraine [CM]) reported in the phase II/III trial for rimegepant (NCT03732638). Four efficacy outcomes were compared between the two erenumab regimens (70 mg and 140 mg) and rimegepant, including changes in MMDs from baseline to month 1 and month 3, changes in Migraine-Specific Quality of Life Questionnaire role function - restrictive domain score from baseline to month 3, and change in disability from baseline to Month 3.

Results:

Compared with rimegepant, erenumab 70 mg was associated with a statistically significant reduction in MMDs at month 3 (-0.90 [-1.76, -0.03]; p = 0.042) and erenumab 140 mg was associated with statistically significant reductions in MMDs at month 1 (-0.94 [-1.70, -0.19]; p = 0.014) and month 3 (-1.28 [-2.17, -0.40]; p = 0.005). The erenumab regimens also had numerical advantages over rimegepant for other efficacy outcomes.

Conclusion:

In the present study, we found that erenumab had a more favorable efficacy profile than rimegepant in reducing MMDs at month 1 and month 3 for migraine prevention. These results may help with decision-making in clinical practice and can be further validated in future clinical trials or real-world studies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Piridinas / Qualidade de Vida / Anticorpos Monoclonais Humanizados / Transtornos de Enxaqueca Tipo de estudo: Prognostic_studies Aspecto: Patient_preference Limite: Humans Idioma: En Revista: J Comp Eff Res Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Piridinas / Qualidade de Vida / Anticorpos Monoclonais Humanizados / Transtornos de Enxaqueca Tipo de estudo: Prognostic_studies Aspecto: Patient_preference Limite: Humans Idioma: En Revista: J Comp Eff Res Ano de publicação: 2024 Tipo de documento: Article